NCT05748587

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 48 (actual)
• Sponsor: Aswan University Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are: * Is there an association between iron and alpha-synuclein accumulation in ischemic stroke? * Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Conditions

• Brain Ischemia

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Serum Iron	Serum iron levels in study groups
DIAGNOSTIC_TEST	RBCs Alpha-synuclein	α-syn levels in RBCs
DIAGNOSTIC_TEST	Serum Soluble lymphocyte activation gene	sLAG-3 in the serum of study groups
RADIATION	Brain computed tomography	Brain CT of patients after admission
DIAGNOSTIC_TEST	Brain Iron	Iron in brain homogenate of rats
DIAGNOSTIC_TEST	Brain Alpha-synuclein	α-syn expression in rat's brain
DIAGNOSTIC_TEST	Brain lymphocyte activation gene	LAG-3 expression in rat's brain
DRUG	Deferoxamine	intramuscular deferoxamine (200 mg/kg) injection to rats

Timeline

• Start date: 2023-04-01
• Primary completion: 2024-03-01
• Completion: 2024-04-01
• First posted: 2023-02-28
• Last updated: 2024-06-25

Locations

1 site across 1 country: Egypt